Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The price tag on progress--chemotherapy for colorectal cancer.

× No keyword cloud information.

117 in total

1. Cost of care for colorectal cancer in Ireland: a health care payer perspective.

Authors: L Tilson; L Sharp; C Usher; C Walsh; Whyte S; A O'Ceilleachair; C Stuart; B Mehigan; M John Kennedy; P Tappenden; J Chilcott; A Staines; H Comber; M Barry
Journal: Eur J Health Econ Date: 2011-06-03

2. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Authors: Sam J Lubner; Michelle R Mahoney; Jill L Kolesar; Noelle K Loconte; George P Kim; Henry C Pitot; Philip A Philip; Joel Picus; Wei-Peng Yong; Lisa Horvath; Guy Van Hazel; Charles E Erlichman; Kyle D Holen
Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544

3. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

Authors: Howard L McLeod; Daniel J Sargent; Sharon Marsh; Erin M Green; Cristi R King; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Stephen N Thibodeau; Axel Grothey; Roscoe F Morton; Richard M Goldberg
Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544

The price tag on progress--chemotherapy for colorectal cancer.

1. Cost of care for colorectal cancer in Ireland: a health care payer perspective.

2. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

3. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

4. Is there such a thing as a cancer treatment that isn't worth its cost?

5. Variation and consternation: access to unfunded cancer drugs in Canada.

6. Economics of cancer care.

7. Refocusing the debate: evidence-based clinical cancer research versus marketplace reality.

8. The impact of anaemia and its treatment on employee disability and medical costs.

Review 9. The financial burden of destination left ventricular assist device therapy: who and when?

10. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.